Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Eganelisib |
Trade Name | |
Synonyms | IPI 549|IPI549|IPI-549 |
Drug Descriptions |
Eganelisib is a selective PI3Kgamma inhibitor, which potentially results in enhanced anti-tumor immune response via T-cell activation and inhibition of tumor growth (PMID: 27828943, PMID: 37000164). |
DrugClasses | PIK3CG inhibitor 10 |
CAS Registry Number | 1693758-51-8 |
NCIT ID | C125471 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Bevacizumab + Eganelisib | Atezolizumab Bevacizumab Eganelisib | 0 | 1 |
Atezolizumab + Eganelisib | Atezolizumab Eganelisib | 0 | 0 |
Atezolizumab + Eganelisib + Nab-paclitaxel | Atezolizumab Eganelisib Nab-paclitaxel | 0 | 1 |
Eganelisib | Eganelisib | 0 | 2 |
Eganelisib + Etrumadenant + Pegylated liposomal doxorubicin | Eganelisib Etrumadenant Pegylated liposomal doxorubicin | 0 | 1 |
Eganelisib + Nivolumab | Eganelisib Nivolumab | 0 | 1 |